Hyperammonemia not caused by liver failure …

Neurogenetic Disorders

Updated 03.04.2024
Released 07.15.1999
Expires For CME 03.04.2027

Hyperammonemia not caused by liver failure

Authors: Kimberly A Chapman MD PhD, Nicholas Ah Mew MD

See Contributor Disclosures

Editor: Barry Wolf MD PhD

Hyperammonemia not caused by liver failure

In This Article

Quick Link

Introduction

Overview

The authors of this article discuss causes of hyperammonemia unrelated to liver failure. They provide information on differential diagnosis and testing to promptly identify these disorders. A basic outline of treatment is provided to help prevent long-term neurologic complications.

Key points

	• Not all hyperammonemia is caused by acquired liver disease. Consider vascular liver bypass, medications, and metabolic diseases, including urea cycle disorders, organic acidemias, transporter defects, and energy-deficient states.
	• Drugs that mimic metabolic disease or situations that increase protein catabolism to a degree that overwhelms urea cycle enzymes can cause hyperammonemia.
	• Identify, diagnose, and treat hyperammonemia quickly (hours, not days) because the duration of hyperammonemia is positively correlated with long-term neurologic complications.

Historical note and terminology

Hyperammonemia is defined as plasma ammonia concentrations greater than 110 μmol/L (186 mg/dL) in healthy neonates. Sick neonates can have plasma ammonia concentrations as high as 180 μmol/L (305 mg/dL) without having an underlying metabolic cause. After the neonatal period, hyperammonemia is considered as concentrations greater than 80 μmol/L (135 mg/dL) (29).

In 1963, Russell and colleagues described a child with hyperammonemia unrelated to liver failure caused by a defect in the biosynthesis of urea (20). By 1965, Wilmanns published a review of a new class of inborn errors called “urea cycle disorders,” which caused hyperammonemia that was not related to liver failure (28). Other inherited disorders of metabolism were identified that increased plasma ammonia concentrations, including defects in all the enzymes of the urea cycle and specific organic acidemias (eg, propionic acidemia and methylmalonic acidemia). Abnormal mitochondrial transport of precursors was also identified as a cause of hyperammonemia. In the early 1980s, some causes of Reye syndrome, in which hyperammonemia is a characteristic finding, were identified as being due to fatty acid oxidation defects, mitochondrial disease (often with concurrent liver failure), and carnitine transporter defects.

Metabolic diseases that cause hyperammonemia can be categorized into those that involve nitrogen metabolism and excretion (predominately urea cycle defects) and those with metabolites or toxins that inhibit urea cycle function or prevent adequate energy for its normal function (eg, organic acidemias, mitochondrial disorders, and fatty acid oxidation defects) (03; 02; 04). Other conditions that can cause hyperammonemia include those that prevent delivery of nitrogen to the liver (eg, portosystemic bypasses and patent ductus venosus), or those that cause increased ammonia production by stimulating protein catabolism (eg, crush injuries, tumor lysis syndrome, lung transplantation, and status epilepticus).

Clinical manifestations

Presentation and course

The clinical manifestations of hyperammonemia are dependent on the cause, the age of the individual, and the rapidity with which ammonia accumulates. Neonates with hyperammonemia can deteriorate within a few hours, initially exhibiting lethargy and poor feeding and progressing to encephalopathy with coma, temperature instability, loss of reflexes, and intracranial hemorrhage. Infants and children may exhibit failure to thrive, feeding problems, vomiting, chronic neurologic symptoms, intermittent encephalopathy with lethargy, ataxia, and seizures due to episodic hyperammonemia. In adolescents and adults, the symptoms of hyperammonemia may be mild ataxia or headaches, chronic neurologic or psychiatric symptoms, behavior problems, episodes of confusion, disorientation, lethargy, or psychosis, and symptoms are usually associated with catabolic stress or high protein intake. Often, adolescents and adults have had symptoms since childhood, but they were misdiagnosed. Metabolic disorders that cause hyperammonemia usually present during the neonatal period, with a second peak incidence as children (10 to 14 years of age), possibly due to the onset of puberty.

Prognosis and complications

Prognosis is dependent on the degree of hyperammonemia and the length of time an individual has hyperammonemia over his or her lifetime. As a result, early detection of hyperammonemia and treatment are essential.

Prognosis is improving with earlier detection and better treatment modalities of the hyperammonemia. Long-term prognosis remains dependent on the number and frequency of metabolic decompensations and on the underlying diagnosis (25; 01). Neurocognitive outcomes are primarily related to the peak and age of the hyperammonemic crises (18). The severity of hyperammonemia crises may be reduced in children with citrullinemia type 1 and argininosuccinic aciduria identified by newborn screening, but the number of episodes of hyperammonemia is not decreased (19). There may be subtle neurocognitive differences between urea cycle disorder subtypes (26; 27).

Clinical vignette

Case 1 (composite fictional patient). Baby boy 1 is a 60-hour-old infant born to a 22-year-old gravida 1, para 1 mother who had an uncomplicated pregnancy. The infant refused to feed and was lethargic. Due to these findings, the infant underwent analysis of his cerebrospinal fluid, urine, and blood for infection; bacterial, viral, and fungal cultures were all negative. A comprehensive metabolic panel, including serum transaminases, and a complete blood count were unremarkable for age. Plasma ammonia concentration was 1400 μmol/L (normal < 180 μmol/L). Family history was significant for a maternal uncle who died as a neonate with “sepsis” and a mother who avoided dietary protein. The infant was treated with hemodialysis within 4 hours of identifying the hyperammonemia. Plasma amino acid analysis obtained prior to hemodialysis showed a low citrulline (1 μmol/L) and arginine (12 μmol/L) concentration. Urinary organic acid analysis showed markedly elevated levels of orotic acid. Sequencing of the X-linked ornithine transcarbamoylase (OTC) gene showed a known causative mutation confirming OTC deficiency. The infant was maintained on a low-protein diet, including nitrogen scavengers and supplemental citrulline until he had a liver transplant at the age of 6 months.

Case 2 (composite fictional patient). Baby girl 2 is a 5-day-old infant born to a 36-year-old gravida 4, para 4 following an uncomplicated pregnancy. The infant had decreasing oral intake and increasing lethargy over 24 hours; therefore, she was brought to the emergency room with probable diagnosis of sepsis. The infant was found to have metabolic acidosis. Bacterial and viral cultures were collected from urine, blood, and cerebrospinal fluid. Comprehensive metabolic panel revealed serum bicarbonate of 7 mg/dL. Plasma amino acid analysis showed an elevated glycine concentration. Plasma ammonia was 800 μmol/L. While in the process of establishing access for hemodialysis because of the elevated ammonia, the primary care physician was informed that infant had an elevated propionylcarnitine on her newborn screen. A week after being drawn in the emergency room, this was confirmed on plasma acylcarnitine profile. Urine organic acid analysis obtained prior to hemodialysis indicated elevated methylcitrate and hydroxypropionate without elevated methylmalonic acid. These findings were consistent with her having propionic acidemia. The infant was treated with hemodialysis to decrease her ammonia and acidemia. She was maintained on dextrose-rich fluids and, following dialysis, was started on a diet appropriate for treating her propionic acidemia.

Biological basis

Etiology and pathogenesis

The etiology of hyperammonemia includes:

	• Urea cycle abnormalities (inability to metabolize nitrogen to water-soluble forms) (05)
	• Inhibition of urea cycle enzyme activity by toxins, lack of energy, or lack of required components (transporters at the cellular level or liver vascular bypass at the organ level)
	• Overwhelming ammonia production (eg, seizure, crush injury, or cell lysis)

Hyperammonemia affects the brain directly by altering its ability to use N-methyl-D-aspartate (NMDA) and glutamate as signals, resulting in central respiratory alkalosis.

Table 1. Disorders That Cause Hyperammonemia

Disorder	Pathogenesis and pathophysiology	Biochemical findings	Gene and other notes
Urea cycle
N-acetylglutamate synthase (NAGS) deficiency	Inability to synthesize N-acetylglutamate from glutamate	PAA: decreased to normal citrulline and arginine UOA: normal orotic acid	NAGS Treat with carbamylglutamate
Carbamyl phosphate synthase I (CPSI) deficiency	Inability of CPSI to combine ammonia to bicarbonate	PAA: decreased to normal citrulline and arginine UOA: normal orotic acid	CPSI Requires N-acetylglutamine for function
Ornithine transcarbamylase (OTC) deficiency	Inability of OTC to combine carbamyl phosphate to ornithine, producing citrulline	PAA: decreased to normal citrulline and arginine UOA: elevated orotic acid	X-linked OTC
Argininosuccinate synthase (ASS) deficiency	Inability of ASS to combine citrulline to aspartate	PAA: markedly increased citrulline and decreased arginine UOA: increased orotic acid	ASS
Argininosuccinate lyase (ASL) deficiency	Inability to metabolize the cleavage of argininosuccinate to fumarate and arginine	PAA: increased arginosuccinate acid; normal to moderately increased citrulline and decreased arginine UAA: markedly increased arginosuccinic acid	ASL
Arginase deficiency	Inability to split arginine into urea and ornithine	PAA: increased arginine UOA: normal to increased orotic acid	ARG
Citrin deficiency	Transporter of aspartate	PAA: increased citrulline	SLC25A13 Galactose-free diet, high-protein diet
Hyperornithinemia-hyperammonemia-homocitrullinuria (HHH)	Inability to transport ornithine between cytoplasm and mitochondrion	PAA: increased ornithine and normal arginine and citrulline UAA: increased ornithine and homocitrulline	Clotting disorder of factor VII and X
Lysinuric protein intolerance	Transporter of dibasic amino acids	Increased plasma LDH and ferritin UAA: increased arginine, lysine, and ornithine PAA: normal to decreased arginine, lysine, ornithine; normal to increased citrulline	Finland
Hypoprolinemia	Delta1-pyrroline-5-carboxylate (P5C) synthase is required to produce ornithine from glutamate	PAA: decreased proline, ornithine, arginine, and citrulline
Hyperinsulinism-hyperammonemia syndrome	Congenital hyperinsulinemia	Hypoglycemia Elevated serum insulin	GLDH
Carbonic anhydrase VA deficiency	Inability to provide bicarbonate to the urea cycle and carboxylases	Hypoglycemia PAA: increased glutamine, alanine, and low-to-normal citrulline UOA: carboxylase substrates	CA5A
Organic acidemias
Propionic acidemia (propionyl-CoA carboxylase deficiency)	Inability of propionyl-CoA carboxylase to metabolize propionyl-CoA to methylmalonyl-CoA. Propionic acid inhibits CPSI activity. Overall energy deficiency	ACP: elevated propionylcarnitine (C3) UOA: elevated 3-hydroxypropionic acid and methylcitrate	PCCA PCCB
Methylmalonic acidemia, cobalamin C/D deficiency	Inability of methylmalonyl mutase to metabolize methylmalonyl-CoA to succinyl-CoA (B12/cobalamin-requiring enzyme). Propionic acid inhibits CPSI activity. Question of overall energy	UOA and plasma organic acids: elevated methylmalonic acid ACP: elevated propionylcarnitine (C3) UOA: elevated 3-hydroxypropionic acid and methylcitrate PAA: elevated homocysteine for cobalamin C/D	Methylmalonyl mutase (MM) MMACHC C2orf25
Isovaleric acidemia	Inability of isovaleryl-CoA dehydrogenase to metabolize isovaleryl-CoA to 3-methylcrotonyl-CoA	UOA: increased isovaleryl-glycine and 3-hydroxyisovaleric acid ACP: increased isovaleryl carnitine (C5)	IVD
Maple syrup urine disease (MSUD)	Deficiency of branched-chain keto dehydrogenase	PAA: elevated leucine and presence of alloisoleucine
Other
Vascular bypass	Ammonia is not delivered to the liver
Cardiopulmonary bypass	Hepatic damage due to bypass
Orthotopic lung transplant	Hepatic glutamine synthase enzyme deficiency
Urease bacterial overgrowth	Overproduction of ammonia		eg, gastric bypass or urea plasma sepsis
Transient hyperammonemia of the newborn	Immaturity of liver enzymes	Elevated plasma ammonia	Infancy only, resolves with time and maturity
Drugs: 5’fluorouracil valproic acid cyclophosphamide	Increased renal ammonia, decreased glutamine synthetase activity, and inhibition of CPSI activity
5-pentanoic acid (Jamaican vomiting sickness)	Ackee fruit-hypoglycin A and B inhibition of urea cycle enzymes
Carbamazepine
Asparaginase
Methanol intoxication
Olanzapine
Oxaliplatin
Glufosinate-ammonium
Capecitabine
Energy deficiencies
Fatty acid oxidation defects	Secondary liver cell dysfunction due to energy deficiency	Specific metabolites consistent with specific disorder on UOA and ACP	Medium-chain acyl-CoA, long-chain acyl-CoA, and very long-chain hydroxyacyl-CoA deficiencies, carnitine palmitoyltransferase 1 and 2.
Mitochondrial defects	Energy deficiency and acidosis	Usually increased lactate, diagnosis-specific changes on muscle biopsy, and electron-chain transport abnormalities. Multiple organ dysfunctions.	Especially mitochondrial depletion syndromes
(PAA: plasma amino acids, UOA: urinary organic acids, UAA: urinary amino acids, ACP: acylcarnitine profile)

Several other inborn errors of metabolism, such as tyrosinemia I and galactosemia, can cause generalized liver dysfunction or failure resulting in hyperammonemia.

Differential diagnosis

Table 2. Differential Diagnosis of Hyperammonemia Not Caused By Liver Failure

Urea cycle disorders
	• N-acetylglutamate synthetase deficiency • Carbamoyl phosphate synthetase deficiency • Ornithine transcarbamylase deficiency (most common urea cycle defect) • Citrullinemia type I (argininosuccinate synthetase deficiency) • Argininosuccinic aciduria (argininosuccinate lyase deficiency) • Argininemia (arginase deficiency), mild hyperammonemia, progressive spasticity • Delta-1-pyrroline-5-carboxylate synthetase deficiency (preprandial hyperammonemia is greater than postprandial) • Hyperinsulinism-hyperammonemia-syndrome (glutamate dehydrogenase C-terminal mutation leading to increased oxidation)
Transporters
	• Homocitrullinuria-hyperornithinemia-hyperammonemia syndrome (ornithine transporter I defect) • Lysinuric protein intolerance (y+ L-amino acid transporter 1 defect, SLC7A7 gene defect), often associated with alveolar proteinosis, hemophagocytosis • Citrin deficiency (SLC25A13) • Carnitine palmitoyltransferase deficiency I, and II, usually with hypoglycemia • Carnitine/acylcarnitine translocase deficiency
Organic acidurias
	• Propionic acidemias (propionyl-CoA carboxylase deficiency) • Methylmalonic acidurias, including defects of cobalamin metabolism • 3-hydroxy-3-methylglutaric aciduria (3-hydroxy-3-methylglutaryl-CoA lyase deficiency) • Beta-ketothiolase deficiency (2-methylacetoacetic aciduria) • Pyroglutamic aciduria • Maple syrup urine disease • Isovaleric acidemia
Mitochondrial disorders
	• Pyruvate carboxylase deficiency • Pyruvate dehydrogenase deficiency • TMEM70 • Fumarate hydratase deficiency • Mitochondrial depletion syndromes • Respiratory chain defects (mainly complex 1 and 2 and multiple acyl-CoA dehydrogenase deficiency) • Carbonic anhydrase VA deficiency
Fatty acid beta-oxidation defects
	• Medium-chain acyl-CoA dehydrogenase deficiency (hypoglycemia, Reye-like syndrome) • Very long-chain acyl-CoA dehydrogenase deficiency • Long-chain hydroxyacyl-CoA dehydrogenase/-ketoacyl-CoA thiolase/enoyl-CoA hydratase deficiency • Primary carnitine deficiency
Other
	• TANGO2 mutations • Medications: valproic acid, pivalate-ester-containing antibiotics, 5’fluorouracil, cyclophosphamide, asparaginase, sunitinib • Multiple myeloma • Infections with urease-positive bacteria (blind loop syndrome, neurogenic bladder) • Nutritional arginine or carnitine deficiency (total parenteral nutrition) • Lead intoxication • 5-pentanoic acidemia (Jamaican vomiting sickness) • Orthotopic lung transplant • Seizures (only locally and acutely) • Transient hyperammonemia of the newborn • Infections, particularly herpes simplex • Refeeding syndrome
Vascular
	• Patent ductus venosus Arantii • Vascular malformations with portosystemic bypass • Cardiopulmonary bypass

Diagnostic workup

Once hyperammonemia is identified, a comprehensive metabolic profile, urinalysis, and arterial blood gas should be obtained. Results of these studies should be rapidly available and can suggest further studies to obtain a more definitive diagnosis. If there is coagulopathy or elevated serum transaminase activities, hepatic failure is likely the cause. In the absence of generalized hepatic dysfunction, a specific inborn error of metabolism or anatomic anomaly causing hyperammonemia is likely. The next studies are typically urinary organic acid analysis, plasma acylcarnitine profile, and plasma amino acid analysis (15; 13). Even in an ideal situation, results of these studies still take hours before they are available.

It is important to determine if there is acidosis or alkalosis. In the typical presentation of urea cycle disorders, there is often a respiratory alkalosis. Acidosis may be present if coma has progressed to respiratory depression; this is a late finding. Plasma amino acid analysis can help identify the specific urea cycle disorder. Plasma citrulline concentration will be decreased in the proximal urea cycle, which includes N-acetylglutamate synthase deficiency, carbamyl phosphate synthetase deficiency, and ornithine transcarbamylase deficiency. Plasma citrulline will be markedly elevated in citrullinemia (argininosuccinic acid synthase deficiency) and will be moderately elevated in argininosuccinate lyase deficiency or arginase deficiency. Argininosuccinic acid is present in argininosuccinate lyase deficiency, and arginine is markedly elevated in arginase deficiency. Orotic acid may be elevated in individuals with ornithine transcarbamylase deficiency or more distal defects in the urea cycle.

In the other inborn errors associated with hyperammonemia, metabolic acidosis is typically present. Urinary organic acid analysis or the acylcarnitine profile can be diagnostic. Children with organic acidemias and fatty acid oxidation defects will have specific pathognomonic elevated metabolites in the urine and on the acylcarnitine profile. Those with organic acidemias, including propionic acidemia, methylmalonic acidemia, and isovaleric acidemia, will likely have ketosis, even in the newborn period, whereas those with fatty acid defects will not have ketosis (22; 10).

Individuals with anatomic anomalies resulting in hyperammonemia (patent ductus venosus, portosystemic shunts) may have surprisingly normal plasma amino acids, urinary organic acids, and plasma acylcarnitine profile. Hyperammonemia with normal results on these tests should suggest imaging studies for anatomic lesions.

Management

Treatment should be tailored to the underlying cause of the hyperammonemia. If the cause is a treatable disorder, appropriate therapy should be initiated. If medications are the cause, they should be discontinued; another medication that is known not to cause hyperammonemia should be used. For hyperammonemia associated with vascular bypass, surgical correction and therapies that decrease production of ammonia in the bowel, lactulose and neomycin, and a bowel regimen should be considered. In addition, some therapies used for inborn errors may be appropriate. In fatty acid oxidation defects, treatment includes providing appropriate calories and avoiding causative dietary fatty acids and fasting (12).

Disorders of the urea cycle and severe hyperammonemia require emergent interventions. Acute management includes reducing ammonia production by stopping dietary protein for about 24 hours and reversing catabolism. Consult a metabolic specialist for optimal management. The mainstays of acute management include the following.

Studies of valproic acid-induced hyperammonemia have demonstrated some benefit to using levocarnitine in addition to stopping the valproic acid (07; 11).

Direct removal of ammonia. The best way to reduce plasma ammonia concentration quickly is by dialysis. The faster the flow rate, the faster the clearance. The method employed depends on the affected individual's circumstances and available resources. In general, the best choice for an individual patient depends on whatever method the local treating team is most comfortable with and can be implemented most quickly. Fastest is use of pump-driven dialysis in which an extra corporeal membrane oxygenation (ECMO) pump is used to drive a hemodialysis machine. Other methods are hemofiltration (both arteriovenous and venovenous) and hemodialysis. These are more likely to be available than ECMO-driven dialysis. Note: Peritoneal dialysis is relatively ineffective for acute hyperammonemia and is generally not recommended if these other options are available.

Pharmacological interventions to facilitate alternative pathway excretion of excessive nitrogen. Nitrogen scavenger therapy (available as an intravenous therapy for acute situations and oral therapy for long-term maintenance) and appropriate replacement of deficient intermediates depending on the diagnosis, including arginine (intravenous administration) or citrulline (oral), can be used (09; 08). Intravenous scavengers can be used in organic acidemias in acute situations at the same doses (pharmacological agents are listed in Table 3). Oral dosing for scavengers is listed in Table 4.

Treatment with carglumic acid. Carglumic acid is a stable analog of N-acetylglutamate and is the standard of care treatment for the rarest of the urea cycle disorders, N-acetylglutamate synthetase deficiency. In propionic and methylmalonic acidemia, hyperammonemia may be caused by secondary inhibition of N-acetylglutamate synthetase. Hyperammonemia in propionic and methylmalonic acidemia has been shown to be responsive to carglumic acid.

Table 3. Intravenous Therapeutics for Hyperammonemia

Neonates to young children:
		Loading dose (90 min)	Maintenance dose
Components of infusion solution	Ammonul (sodium phenylacetate and sodium benzoate injection)	2.5 mL/kg (provides 250 mg/kg of sodium phenylacetate and 250 mg/kg of sodium benzoate) Recommended to be diluted in at least 25 mL/kg 10% dextrose solution	2.5 mL/kg/24 hr (provides 250 mg/kg of sodium phenylacetate and 250 mg/kg of sodium benzoate) Recommended to be diluted in at least 25 mL/kg 10% dextrose solution
Components of infusion solution	Arginine HCl injection, 10%	2.0 mL/kg (NAGS, CPSI, OTC deficiencies) or 6.0 mL/kg (unknown, ASS, and ASL deficiencies)	2.0 mL/kg/24 hr (NAGS, CPSI, OTC deficiencies) or 6.0 mL/kg/hr (unknown, ASS, and ASL deficiencies
Older children and adults:
		Loading dose (90 min)	Maintenance dose
Components of infusion solution	Ammonul (sodium phenylacetate and sodium benzoate injection)	55 mL/m2 (provides 5.5 g/m2 of sodium phenylacetate and 5.5 g/m2 of sodium benzoate) Recommended to be diluted in at least 25 mL/kg 10% dextrose solution	55 mL/m2/24 hr (provides 5.5 g/m2 of sodium phenylacetate and 5.5 g/m2 of sodium benzoate) Recommended to be diluted in at least 25 mL/kg 10% dextrose solution
Components of infusion solution	Arginine HCl injection, 10%	2.0 mL/kg (NAGS, CPSI, OTC deficiencies) or 6.0 mL/kg (unknown, ASS, and ASL deficiencies)	2.0 mL/kg (NAGS, CPSI, OTC deficiencies) or 6.0 mL/kg/hr (unknown, ASS, and ASL deficiencies)

Table 4. Oral Dosing for Scavengers

Medication	Dosage
Sodium phenylbutyrate	< 20 kg: 450-600 mg/kg/day > 20 kg: 9.9-13 g/m²/day Doses > 20 g have not been studied
Glycerol phenylbutyrate > 2 years	(Sodium phenylbutyrate naïve) 4.5-11.2 mL/m²/day= 5-12.4 g/m2/day Do not exceed doses > 17.5 mL/day
Sodium benzoate	< 20 kg: 250 mg/kg/day > 20 kg: 5.5 g/m2/day

Nutritional management. In acute hyperammonemia due to inherited metabolic disorders, catabolism of protein, either exogenous or endogenous, is typically the cause. Catabolism is treated with calories from glucose, fats, and essential amino acids. If the underlying diagnosis is due to defects in fatty acid oxidation, calories should be given as glucose and amino acids. Multiple other strategies to reverse catabolism must be employed to convert to an anabolic state. Low-dose, continuous infusion of insulin with maintenance of adequate glucose delivered by continuous delivery of carbohydrate-containing fluids has been used effectively. This must be performed cautiously because these individuals are exquisitely sensitive to insulin. Ensuring adequate stores of essential amino acids with frequent monitoring of plasma concentrations is critical. Complete restriction of protein should not exceed 12 to 24 hours because depletion of essential amino acids results in increased endogenous protein catabolism and nitrogen release.

The only exception to low protein, high carbohydrates is citrin deficiency, which requires high protein and low carbohydrate delivery in the acute and chronic setting to prevent hyperammonemia (21; 14).

For chronic long-term treatment of urea cycle abnormalities once an individual is stable, appropriate protein restriction is the mainstay of therapy. Because these individuals have personal requirements that change with age, they should be followed by a metabolic geneticist and a dietician well versed in the nutritional requirements of such disorders. Excessively low-protein diets can be as harmful as high-protein loads in this population because they induce endogenous protein catabolism and subsequent hyperammonemia (23). For those with fatty acid oxidation defects, constant calorie delivery is essential. For those with urea cycle defects, oral scavenger therapy is useful for eliminating excess nitrogen.

Liver transplant. Liver transplantation has successfully been used to normalize blood ammonia concentrations in urea cycle defects and improves protein tolerance in organic acidemias (06; 17).

References

01: Ah Mew N, Krivitzky L, McCarter R, et al. Clinical outcomes of neonatal onset proximal versus distal urea cycle disorders do not differ. J Pediatr 2013;162(2):324-9.e1. PMID 22901741
02: Bachmann C. Inherited hyperammonemias. In: Blau N, Duran M, Blaskovics ME, Gibson KM, Scriver CR, editors. Physician’s Guide to the Laboratory Diagnosis of Metabolic Diseases. 2nd edition. Berlin: Springer, 2003:261-76.
03: Batshaw ML. Hyperammonemia. Curr Probl Pediatr 1984;14(11):1-69. PMID 6510017
04: Braissant O. Current concepts in the pathogenesis of urea cycle disorders. Mol Genet Metab 2010;100 Suppl 1:S3-S12. PMID 20227314
05: Brusilow SW. Urea cycle disorders: clinical paradigm of hyperammonemic encephalopathy. Prog Liver Dis 1995;13:293-309. PMID 9224507
06: Burdelski M, Ullrich K. Liver transplantation in metabolic disorders: summary of the general discussion. Eur J Pediatr 1999;158 Suppl 2:S95-6. PMID 10603108
07: Cattaneo CI, Ressico F, Valsesia R, D'Innella P, Ballabio M, Fornaro M. Sudden valproate-induced hyperammonemia managed with L-carnitine in a medically healthy bipolar patient: Essential review of the literature and case report. Medicine (Baltimore) 2017;96(39):e8117. PMID 28953637
08: Enns GM. Nitrogen sparing therapy revisited 2009. Mol Genet Metab 2010;100 Suppl 1:S65-71. PMID 20202877
09: Enns GM, Berry SA, Berry GT, Rhead WJ, Brusilow SW, Hamosh A. Survival after treatment with phenylacetate and benzoate for urea-cycle disorders. N Engl J Med 2007;356(22):2282-92. PMID 17538087
10: Filipowicz HR, Ernst SL, Ashurst CL, Pasquali M, Longo N. Metabolic changes associated with hyperammonemia in patients with propionic acidemia. Mol Genet Metab 2006;88(2):123-30. PMID 16406646
11: Glatstein M, Bonifacio Rino P, de Pinho S, Scolnik D, Pivko-Levi D, Hoyte C. Levocarnitine for the treatment of valproic acid-induced hyperammonemic encephalopathy in children: the experience of large, tertiary care pediatric hospital and a poison center. Am J Ther 2019;26(3):e344-9. PMID 29232283
12: Haberle J. Clinical practice: the management of hyperammonemia. Eur J Pediatr 2011;170(1):21-34. PMID 21165747
13: Haberle J, Boddaert N, Burlina A, et al. Suggested guidelines for the diagnosis and management of urea cycle disorders. Orphanet J Rare Dis 2012;7:32. PMID 22642880
14: Inui A, Ko JS, Chongsrisawat V, et al. Update on the diagnosis and management of neonatal intrahepatic cholestasis caused by citrin deficiency: Expert review on behalf of the Asian Pan-Pacific Society for Pediatric Gastroenterology, Hepatology, and Nutrition. J Pediatr Gastroenterol Nutr 2024;78(2):178-87. PMID 38374571
15: Kamboj M. Clinical approach to the diagnoses of inborn errors of metabolism. Pediatr Clin North Am 2008;55(5):1113-27. PMID 18929055
16: Mendez-Figueroa H, Lamance K, Sutton VR, Aagaard-Tillery K, Van den Veyver I. Management of ornithine transcarbamylase deficiency in pregnancy. Am J Perinatol 2010;27(10):775-84. PMID 20458665
17: Posset R, Garbade SF, Gleich F, et al. Long-term effects of medical management on growth and weight in individuals with urea cycle disorders. Sci Rep 2020a;10(1):11948. PMID 32686765
18: Posset R, Garcia-Cazorla A, Valayannopoulos V, et al. Age at disease onset and peak ammonium level rather than interventional variables predict the neurological outcome in urea cycle disorders. J Inherit Metab Dis 2016;39(5):661-72. PMID 27106216
19: Posset R, Kölker S, Gleich F, et al. Severity-adjusted evaluation of newborn screening on the metabolic disease course in individuals with cytosolic urea cycle disorders. Mol Genet Metab 2020b;131(4):390-7. PMID 33288448
20: Russell A, Levin B, Oberholzer VG, Sinclair L. Hyperammonaemia. A new instance of an inborn enzymatic defect of the biosynthesis of urea. Lancet 1962;2(7258):699-700. PMID 13975632
21: Saheki T, Song YZ. Citrin deficiency. In: Adam MP, Ardinger HH, Pagon RA, editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2018. Updated August 2017. PMID 20301360
22: Saudubray JM, Charpentier C. Clinical phenotypes: diagnosis/algorithms. In: Scriver C, Beaudet A, Sly W, Valle D, editors. The Metabolic and Molecular Bases of Inherited Disease. New York: McGraw-Hill, 2001:1327-403.
23: Summar M, Tuchman M. Proceedings of a consensus conference for the management of patients with urea cycle disorders. J Pediatr 2001;138(1 Suppl):S6-10. PMID 11148544
24: Summar ML, Koelker S, Freedenberg D, et al. The incidence of urea cycle disorders. Mol Genet Metab 2013;110(1-2):179-80. PMID 23972786
25: Tuchman M, Lee B, Lichter-Konecki U, et al. Cross-sectional multicenter study of patients with urea cycle disorders in the United States. Mol Genet Metab 2008;94(4):397-402. PMID 18562231
26: Waisbren SE, Cuthbertson D, Burgard P, et al. Biochemical markers and neuropsychological functioning in distal urea cycle disorders. J Inherit Metab Dis 2018;41(4):657-67. PMID 29423830
27: Waisbren SE, Stefanatos AK, Kok TMY, Ozturk-Hismi B. Neuropsychological attributes of urea cycle disorders: a systematic review of the literature. J Inherit Metab Dis 2019;42(6):1176-91. PMID 31268178
28: Wilmanns W. [Inborn errors of the urea cycle.] [Article in German] Dtsch Med Wochenschr 1965;90:888-90. PMID 14282237
29: Zschocke J, Hoffmann GF. Vademecum Metabolicum: Manual of Metabolic Paediatrics. 2nd edition. Friedrichsdorf, Germany: Schattauer, 2004:8-12, 24, 57-70, 75-78, 86-99.

Contributors

All contributors' financial relationships have been reviewed and mitigated to ensure that this and every other article is free from commercial bias.

Authors

Kimberly A Chapman MD PhD

Dr. Chapman of George Washington University and Children’s National Rare Disease Institute received honorariums from HemoShear Therapeutics as principal investigator.
See Profile
Nicholas Ah Mew MD

Dr. Ah Mew of Children's National Medical Center received consultant fees from Moderna and Ultragenyx and fees from iECURE for membership on a drug safety monitoring board.
See Profile

Editor

Barry Wolf MD PhD

Dr. Wolf of Lurie Children's Hospital of Chicago has no relevant financial relationships to disclose.
See Profile

Former Authors

Claude Bachmann MD

Patient Profile

Age range of presentation: 0 months to 65+ years
Sex preponderance: male=female
Heredity: heredity typical

heredity may be a factor

autosomal recessive

X-linked recessive
Population groups selectively affected: none selectively affected
Occupation groups selectively affected: none selectively affected

ICD & OMIM codes

ICD-9: Hyperammonemia: 270.6
ICD-10: Hyperammonemia: E72.2
OMIM: Hyperammonemia due to Argininemia: #207800

Hyperammonemia due to Argininosuccinate lyase deficiency: #207900

Hyperammonemia due to Beta-ketothiolase deficiency: #300438

Hyperammonemia due to Carbamoyl phosphate synthethase I deficiency: #237300

Hyperammonemia due to Carnitine-acylcarnitine translocase deficiency (SLC25A20): #212138

Hyperammonemia due to Carnitine palmitoyl transferase I deficiency: #255120

Hyperammonemia due to Citrullinemia: #215700

Hyperammonemia due to Citrin deficiency (Citrullinemia type II): #603471

Hyperammonemia due to Cobalamin C deficiency: #277400

Hyperammonemia due to Cobalamin D deficiency: #277410

Hyperammonemia due to Delta-1-pyrroline-5-carboxylate synthetase deficiency: #612652

Hyperammonemia due to Fumarate hydratase deficiency: #606812

Hyperammonemia due to 3-hydroxy-3-methylglutaryl-CoA lyase deficiency: +246450

Hyperammonemia due to Hyperinsulinism-hyperammonemia syndrome: #606762

Hyperammonemia due to Hyperornithinemia-hyperammonemia-homocitrullinuria: #238970

Hyperammonemia due to Isovaleric acidemia: #243500

Hyperammonemia due to Long-chain acyl-CoA dehydrogenase deficiency: #609016, #609015

Hyperammonemia due to Lysinuric protein intolerance: #222700

Hyperammonemia due to Maple syrup urine disease: #248600

Hyperammonemia due to Medium-chain acyl-CoA dehydrogenase deficiency: #201450

Hyperammonemia due to Methylmalonyl-CoA mutase deficiency: #251000

Hyperammonemia due to Mitochondrial complex I deficiency: #252010

Hyperammonemia due to Mitochondrial complex II deficiency: #252011

Hyperammonemia due to Multiple acyl-CoA dehydrogenase deficiency: #231680

Hyperammonemia due to N-acetylglutamate synthase: *608300

Hyperammonemia due to Ornithine transcarbamylase deficiency: #311250

Hyperammonemia due to Propionic acidemia: #606054

Hyperammonemia due to Pyruvate carboxylase: #266150

Hyperammonemia due to Solute carrier family 25 (mitochondrial carrier, ornithine transporter), member 2: *608157

Hyperammonemia due to Very long-chain acyl-CoA dehydrogenase deficiency: #201475

This is an article preview.
Start a Free Account
to access the full version.

Nearly 3,000 illustrations, including video clips of neurologic disorders.
Every article is reviewed by our esteemed Editorial Board for accuracy and currency.
Full spectrum of neurology in 1,200 comprehensive articles.
Listen to MedLink on the go with Audio versions of each article.

Questions or Comment?

MedLink®, LLC

3525 Del Mar Heights Rd, Ste 304
San Diego, CA 92130-2122

Toll Free (U.S. + Canada): 800-452-2400

US Number: +1-619-640-4660

Support: service@medlink.com

Editor: editor@medlink.com

ISSN: 2831-9125

Hyperammonemia not caused by liver failure

Associated Disorders

Psychiatric diseases
Seizures
Sepsis

Differential Diagnosis

3-hydroxy-3-methyl glutaric aciduria
3-hydroxy-3-methylglutaryl-CoA lyase deficiency
arginine deficiency
argininosuccinic aciduria
argininemia mild hyperammonemia
- asparaginase treatment
- beta-ketothiolase deficiency
- cancer treatment with 5-fluorouracil
- carbonic anhydrase VA deficiency
- carnitine/acylcarnitine translocase deficiency
- carnitine palmitoyltransferase I deficiency
- carbamoyl phosphate synthetase deficiency
- citrullinemia type I and type II
- delta-1-pyrroline 5-carboxylate synthetase deficiency
- fatty acid beta-oxidation defects
- fumarate hydratase deficiency
- hyperinsulinism-hyperammonemia syndrome
- hyperornithinemia-hyperammonemia-homocitrullinuria syndrome
- hypoketonemia
- hypoglycemia
- iatrogenic: valproate administration, pivalate ester-containing antibiotics
- infections with urease-positive bacteria
- lead intoxication
- long-chain hydroxyacyl-CoA dehydrogenase/ketoacyl-CoA thiolase/enoyl-CoA hydratase deficiency
- lysinuric protein intolerance
- medium-chain acyl-CoA dehydrogenase deficiency
- methylmalonic acidurias, including defects of cobalamine metabolism
- N-acetylglutamate synthetase deficiency
- nutritional arginine deficiency
- organic acidurias
- ornithine transcarbamylase deficiency
- patent ductus venosus Arantii
- progressive spasticity
- propionic acidemias
- propionyl CoA carboxylase deficiency
- pyroglutamic aciduria
- pyruvate carboxylase deficiency
- pyruvate dehydrogenase deficiency
- respiratory chain defects (mainly complex 1 and 2 and glutaric aciduria type 2)
- Reye-like syndrome
- TANGO2 mutations
- TMEM70 mutations
- transient hyperammonemia of the premature
- urea cycle disorders
- vascular malformations with portosystemic bypass
- very long-chain acyl-CoA dehydrogenase deficiency

Also Relevant

Argininosuccinic acidemia
Carbamoyl phosphate synthetase 1 deficiency
Carnitine palmitoyltransferase 1A deficiency
Carnitine palmitoyltransferase II deficiency
Carnitine-acylcarnitine translocase deficiency
- Citrullinemias types 1 and 2
- Hepatic encephalopathy
- Hepatorenal tyrosinemia
- HHH syndrome
- Hyperargininemia
- Medium-chain acyl-CoA dehydrogenase deficiency
- N-acetylglutamate synthase deficiency
- Ornithine transcarbamylase deficiency
- Pyruvate carboxylase deficiency

Clinical Categories

Neurogenetic Disorders

Web References

Guidelines

NORD: Urea cycle disorders

Hyperammonemia not caused by liver failure

Introduction

Overview

Key points

Historical note and terminology

Clinical manifestations

Presentation and course

Prognosis and complications

Clinical vignette

Biological basis

Etiology and pathogenesis

Table 1. Disorders That Cause Hyperammonemia

Epidemiology

Prevention

Differential diagnosis

Table 2. Differential Diagnosis of Hyperammonemia Not Caused By Liver Failure

Diagnostic workup

Management

Table 3. Intravenous Therapeutics for Hyperammonemia

Table 4. Oral Dosing for Scavengers

Special considerations

Pregnancy

Anesthesia

References

Contributors

Authors

Editor

Former Authors

Patient Profile

ICD & OMIM codes

This is an article preview. Start a Free Account to access the full version.

Questions or Comment?

Also in This Category

Vanishing white matter disease

Wilson disease

White matter abnormalities in the brain

Hypermethioninemia

POLG-related mitochondrial disorders

Multiple acyl-CoA dehydrogenase deficiency

Medium-chain acyl-CoA dehydrogenase deficiency

Long-chain fatty acid oxidation defects

This is an article preview.
Start a Free Account
to access the full version.